Eagle Pharmaceuticals launched its IPO after having priced its offering of 3,350,000 shares at $15 per share. The stock began trading Wednesday on the NASDAQ under the ticker symbol “EGRX.” Piper Jaffray & Co. and William Blair & Company are the lead underwriters. Based in Woodcliff Lake, NJ, Eagle Pharmaceuticals is a specialty pharmaceutical company.
WOODCLIFF LAKE, N.J., Feb 11, 2014 (BUSINESS WIRE) — EAGLE PHARMACEUTICALS, INC. (“EAGLE”) EGRX +1.47% announced today the pricing of its initial public offering of 3,350,000 shares of common stock at a price to the public of $15.00 per share. The shares are scheduled to begin trading on the NASDAQ Global Market under the ticker symbol “EGRX” on February 12, 2014. Eagle is offering all of the shares of common stock. Eagle has also granted the underwriters a 30-day option to purchase up to an additional 502,500 shares of common stock. The offering is expected to close on February 18, 2014, subject to customary closing conditions.
Piper Jaffray & Co. and William Blair & Company, L.L.C. are acting as joint book-running managers. Cantor Fitzgerald & Co. is acting as co-manager.
The Securities and Exchange Commission declared effective a registration statement relating to these securities on February 11, 2014. The offering is being made only by means of a prospectus. A copy of the prospectus relating to the offering may be obtained from Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, Suite 1000, Minneapolis, MN 55402, or by telephone at (800) 747-3924, or by email at [email protected] , or from William Blair & Company, L.L.C., 222 W. Adams St., Chicago, IL 60606, or by email at [email protected] or by telephone at (800) 621-0687.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Eagle is a specialty pharmaceutical company focused on developing and commercializing injectable products utilizing the FDA’s 505(b)(2) regulatory pathway. The company develops products that address the shortcomings, as identified by physicians, pharmacists and other stakeholders, of existing commercially successful injectable products.